"Guanidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
| Descriptor ID |
D006146
|
| MeSH Number(s) |
D02.078.370
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Guanidines".
Below are MeSH descriptors whose meaning is more specific than "Guanidines".
This graph shows the total number of publications written about "Guanidines" by people in this website by year, and whether "Guanidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 4 | 5 | 9 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 4 | 9 | 13 |
| 2021 | 6 | 3 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Guanidines" by people in Profiles.
-
OFF-State-Specific Inhibition of the Proprotein Convertase Furin. ACS Chem Biol. 2021 09 17; 16(9):1692-1700.
-
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. Trials. 2021 Aug 19; 22(1):550.
-
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. J Virol. 2021 10 13; 95(21):e0097521.
-
Development of an alternative saliva test for diagnosis of SARS-CoV-2 using TRIzol: Adapting to countries with lower incomes looking for a large-scale detection program. PLoS One. 2021; 16(8):e0255807.
-
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. mBio. 2021 08 31; 12(4):e0097021.
-
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians. Pulm Pharmacol Ther. 2021 10; 70:102055.
-
Determination of camostat and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method. Clin Biochem. 2021 Oct; 96:56-62.
-
Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings. Med Microbiol Immunol. 2021 Aug; 210(4):235-244.
-
Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment. Int J Mol Sci. 2021 Jun 30; 22(13).
-
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021 07 20; 36(3):109415.